Metavention

Focus: Metavention is a biotechnology company focused on metabolic neuromodulation therapy, headquartered in Maple Grove, Minnesota. The company develops innovative implantable systems targeting metabolic diseases through organ denervation approaches.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Metavention

AI assessmentNot Hiring

No open roles listed right now. Follow Metavention to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Metabolic Neuromodulation System

Diabetes

N/A

Clinical Trials (1)

NCT02278068COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy

N/A

Help build intelligence for Metavention

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape a novel therapeutic modality (metabolic neuromodulation) with significant unmet need in diabetes and hypertension markets
Multi-program pipeline across denervation indications (renal, hepatic, multi-organ) suggests diversified clinical strategy and long-term job security
Ground-floor position at pre-revenue biotech offers equity upside potential and hands-on involvement in company building

Watch Out For

No active hiring (0 open positions) indicates company is in stealth/lean mode, limiting near-term career entry opportunities
Absence of published clinical trial data, FDA phase designations, or recent news raises visibility and validation concerns about pipeline maturity

Generated by Claude from Metavention's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

iRF System Renal Denervation

Hypertension

N/A

Clinical Trials (1)

NCT04740723Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension

N/A

iRF System Hepatic Denervation

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT04285554Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

N/A